PMID- 30521801
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20190318
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 489
DP  - 2019 Feb
TI  - A value proposition for trough level-based anti-TNFalpha drug dosing.
PG  - 89-95
LID - S0009-8981(18)30619-3 [pii]
LID - 10.1016/j.cca.2018.11.038 [doi]
AB  - Treatment of inflammatory bowel diseases and rheumatic disorders with anti-tumor 
      necrosis factor alpha (TNFalpha) drugs is expensive, while a significant proportion 
      of patients does not show adequate clinical response. Therapeutic drug monitoring 
      (TDM) enables patient-specific anti-TNFalpha therapy. The role of laboratory tests in 
      clinical care has recently been described in a value proposition framework. It 
      describes care processes, stakeholders, costs, risks, benefits and patient 
      outcomes based on the use of a laboratory test in a clinical care pathway. We 
      have applied this concept to the use of TDM for anti-TNFalpha drugs, describing 
      evidence that supports the intervention and its cost effectiveness, steps that 
      need to be adjusted in the care pathway, possible treatment algorithms and 
      measures to assess adoption of this framework into clinical practice. For 
      effective TDM, an assay for measurement of drug levels together with appropriate 
      target ranges and an anti-drug-antibody assay have to be implemented. Also, 
      instead of only reporting the drug concentration, laboratorians, pharmacists and 
      clinicians should deliver added value by introducing a TDM-based treatment 
      algorithm into clinical practice. Thus, to maximize effectiveness of TDM of 
      anti-TNFalpha therapy in routine care, adjustment of current care pathways and 
      cooperation of many stakeholders are needed.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Scharnhorst, V
AU  - Scharnhorst V
AD  - Expert Center Clinical Chemistry Eindhoven, Eindhoven, the Netherlands; Clinical 
      Laboratory, Catharina Hospital, Eindhoven, the Netherlands; Laboratory of 
      Chemical Biology and Institute for Complex Molecular Systems, Eindhoven 
      University of Technology, Eindhoven, the Netherlands. Electronic address: 
      volkher.scharnhorst@catharinaziekenhuis.nl.
FAU - Schmitz, E M H
AU  - Schmitz EMH
AD  - Expert Center Clinical Chemistry Eindhoven, Eindhoven, the Netherlands; Clinical 
      Laboratory, Catharina Hospital, Eindhoven, the Netherlands; Laboratory of 
      Chemical Biology and Institute for Complex Molecular Systems, Eindhoven 
      University of Technology, Eindhoven, the Netherlands; Clinical Laboratory, Maxima 
      Medical Center, Veldhoven, the Netherlands.
FAU - van de Kerkhof, D
AU  - van de Kerkhof D
AD  - Expert Center Clinical Chemistry Eindhoven, Eindhoven, the Netherlands; Clinical 
      Laboratory, Catharina Hospital, Eindhoven, the Netherlands.
FAU - Derijks, L J J
AU  - Derijks LJJ
AD  - Department of Clinical Pharmacy and Pharmacology, Maxima Medical Center, 
      Veldhoven, the Netherlands.
FAU - Broeren, M A C
AU  - Broeren MAC
AD  - Expert Center Clinical Chemistry Eindhoven, Eindhoven, the Netherlands; Clinical 
      Laboratory, Maxima Medical Center, Veldhoven, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20181203
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology/therapeutic use
MH  - Dose-Response Relationship, Immunologic
MH  - Drug Monitoring/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Tumor Necrosis Factor-alpha/*immunology
EDAT- 2018/12/07 06:00
MHDA- 2019/03/19 06:00
CRDT- 2018/12/07 06:00
PHST- 2018/09/27 00:00 [received]
PHST- 2018/11/20 00:00 [revised]
PHST- 2018/11/30 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2018/12/07 06:00 [entrez]
AID - S0009-8981(18)30619-3 [pii]
AID - 10.1016/j.cca.2018.11.038 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2019 Feb;489:89-95. doi: 10.1016/j.cca.2018.11.038. Epub 2018 Dec 
      3.